News

The European Medicines Verification Organization (EMVO) has launched a newsletter, which informs about the National Medicines Verification Organization (NMVO) and the European Change Control Board (EU CCB) created by the EMVO, various working groups – IT, quality, as well as the Inter-Operability Testing group, which allows for more efficient management of the medicines verification system and improvement of its development in all Member States.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.20)”.

EMVO Community Newsletter June 2022 you will find an overview of the latest developments and activities in our community, starting with a deep dive into the end of the stabilisation period in Ireland and finishing off with a summary of the best practices on Product Code Unknown (A1).

EMVO have issued the next EMVS Community Newsletter – March 2022. The Newsletter aims to inform about the Alert Management System, best practices on reducing alerts from the point of view of the Romanian NMVO.

European Commission (EC) has published a new version of the Questions & Answers document on “Safety Features for Medicinal Products for Human Use (V.19)”.

The European Commission has taken decision to extend the transitional period for a period of three years, which was determined in the context of the action of the medicine verification system regarding the medicine products exported to the United Kingdom* (UK) following its’ withdrew from the European Union.